<DOC>
	<DOC>NCT00623779</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.</brief_summary>
	<brief_title>Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Either one of the following risk factors is sufficient for inclusion (high risk patient) Previous cerebral ischaemic attack (stroke or transient ischaemic attack (TIA), &gt;30 days prior to randomization) Previous systemic embolism or at least one of the following risk factors are needed for inclusion: Age â‰¥75 years Symptomatic congestive heart failure Impaired left ventricular systolic function Diabetes mellitus; Hypertension requiring antihypertensive treatment In addition to AF the patient must be appropriate for but unable or unwilling to take VKA therapy Presence of a clinically significant valvular heart disease;; Stroke or TIA and/or systemic embolism within the previous 30 days prior to randomization Conditions associated with increased risk of major bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>